Approximately 40%
of population will be
diagnosed with cancer
at some point during their
lifetimes.
Although there has been some progress in cancer treatment, the outlook remains grim for many aggressive cancers.
Disease complexity in aggressive cancers has limited progress.
New engineering tools are needed to resolve this complexity, to guide treatment planning, to improve patient outcomes.

    CHANGE IN FIVE-YEAR SURVIVORSHIP FROM 1970 TO 2013 1

    Image

    Sumaq Life LLC is currently working with research partners at Texas A&M University to develop an explainable AI approach to design personalized cancer treatment. Explainable AI uses models of complex gene regulatory networks involved in cancer development to target therapy with a better likelihood of success.

    These models have been used to identify key drug targets that have demonstrated remarkable success in achieving robust cancer cell killing in several aggressive cancer cell lines, including metastatic melanoma1, osteosarcoma2, breast3, pancreatic4, lung5, and colorectal6 cancer.

    Image

    Cancer Gene Regulatory Network Models

    Image

    Explainable AI Software

    Sumaq Life LLC and its partners are currently developing medical software that will integrate with a practice’s EMR system to (1) identify patients who qualify for genomic testing, and (2) develop personalized treatment plans based on test results and gene regulatory modeling. This explainable AI approach allows for both single agent and multi-agent therapy, which has been shown to improve cancer killing.

    Patient:

    Improve survivorship while reducing treatment toxicity that impacts quality of life.

    Providers:

    Identify patients who qualify for molecular profiling. Evaluate patient specific gene mutations in order to design more effective treatment.

    Payors:

    Improve patient outcomes while avoiding ineffective and costly treatments.

    Pharmaceutical Companies:

    Increase compliance with national guidelines for genomic medicine. Identify new patient populations that will benefit from FDA approved anticancer drugs.
    Image

    Unlock life opportunities through scientific discovery.

    Sumaq Life was formed to create health-related technological innovations and increase translation of scientific discoveries into real-world applications.

    Great scientific discoveries are not always translated to society. Equally important to strong scientific justification is a viable translation pathway. Sumaq Life serves as a translation vehicle to ensure the impact of scientific discoveries are realized.

    Ask Questions
    Image

    SUMAQ LEADERSHIP TEAM

    Image

    Dr. N. Peter Reeves, PhD

    President and Founder

    Dr. Reeves has a PhD in Biomedical Engineering from Yale University (2007) and is an established researcher specializing in modeling complex biological systems. He has +60 peer-reviewed publications and has served as a PI/Co-PI on approximately $5M in federally funded research.

    Image

    Patricia Gonzales-Lazarte, LLM

    Chief Financial Officer

    Mrs. Gonzales-Lazarte completed her law degree from the University of Lima (Peru), specializing in Corporate Law, and has a Master's in Law from the University of British Columba. She has worked for over 10 years in international consulting firms (Arthur Andersen, BDO), where she advised large national and international corporations on business and tax matters.

    Image

    Dr. Rachad Al Ameen, MBA/PharmD

    Business Strategist

    Dr. Al Ameen received is Doctor of Pharmacy from Wayne State University in 2017 and worked as a clinical pharmacist for CVS Health and later established and managed an independent pharmacy. In 2022, he completed a MBA, with an emphasis on entrepreneurship and finance, from the University of Michigan Ross School of Business.

    SUMAQ AVISORY BOARD

    Image

    Prof. Aniruddha Datta

    J. W. Runyon, Jr. '35 Professor II of Electrical and Computer Engineering at Texas A & M University. A control engineer by training, he successfully retrained in the area of Cancer Genomics under a 2-year National Cancer Institute Training Grant (2001-2003). Since then, his NSF-funded research has focused on utilizing engineering approaches for cancer therapy design, including gene regulatory modeling.

    Image

    Dr. Giuseppe Del Priore

    A practicing oncologist and clinical researcher at Morehouse School of Medicine (>100 peer-reviewed publications). Dr. Del Priore has a Master’s in Public Health in biostatistics and epidemiology, and currently practices at a tertiary care, safety net hospital in inner city Atlanta (Grady Hospital) and a community health center.

    Image

    Mr. Brian Decker

    CEO and Founder of EMOL Health, a medical software company servicing over 315 oncology sites in 30 US states with a growing oncology database of over 4.4 million unique cancer patients. Mr. Decker has an undergraduate degree in computer science from Michigan Technology University and an MBA from the University of Notre Dame.

    Image

    Prof. Kumpati Narendra

    Harold W. Cheel Professor of Electrical Engineering and is the Director of Yale University's Center for System Science. Prof. Narendra specializes in the application of system identification and control across a diverse range of systems, including robotics, aircraft, and medicine.

    Image

    Connect with Sumaq Life

      Call Us Today - 517.316.6613

      Image
      POWERED BY MICHIGANCREATIVE © 2024